Digital Look

Welcome to Digital Look++,
you are not logged in

Benchmark Holdings (BMK)

Pharma and Biotech

24.70p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
31-Mar-25	Interim	40.63	(12.62)	(1.77)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Sep-20	105.57	(22.57)	(3.80)p	n/a	n/a	n/a	n/a	0.0%
30-Sep-21	125.06	(9.18)	(1.93)p	n/a	n/a	n/a	n/a	0.0%
30-Sep-22	157.71	(21.38)	(4.34)p	n/a	n/a	n/a	n/a	0.0%
30-Sep-23	103.96	(24.70)	(3.21)p	n/a	n/a	n/a	n/a	0.0%
30-Sep-24	90.36	(45.92)	(5.99)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Sep-25	79.70	(4.10)	26.63p	0.9	n/a	n/a	n/a	0.0%
30-Sep-26	83.70	11.30	1.10p	22.5	n/a	-96%	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.